C. Calmettes

Combinatory therapy targeting mitochondrial oxidative phosphorylation improves efficacy of IDH mutant inhibitors in acute myeloid leukemia

F. Jourdan, M. Carroll, M. Konopleva, 2019, bioRxiv.

Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis

D. Breilh, V. Latrabe, E. Forcade, 2018, Oncotarget.

Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in Vigibase

P. Fenaux, K. Laribi, G. Miremont-Salamé, 2020, British Journal of Clinical Pharmacology.

Romiplostim (AMG531, Nplate) for secondary failure of platelet recovery after allo-SCT

N. Milpied, R. Tabrizi, C. Calmettes, 2011, Bone Marrow Transplantation.

Romiplostim (AMG531, Nplate®) for Secondary Failure of Platelet Recovery After Allogeneic Stem-Cell Transplantation

N. Milpied, R. Tabrizi, C. Calmettes, 2011 .

Risk Factors for Steroid-Refractory Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation from Matched Related or Unrelated Donors.

M. Labopin, G. Marit, S. Dimicoli-Salazar, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study

X. Leleu, K. Laribi, V. Richez, 2023, Annals of Hematology.

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

M. Macro, C. Touzeau, K. Laribi, 2024, Nature medicine.